Pfizer (PFE) Projected to Post Earnings on Tuesday

Key Points

• Pfizer will report Q1 2026 results before the market opens on Tuesday, May 5 (earnings call 10:00 AM ET); analysts expect $0.77 EPS and $13.894 billion in revenue.
• Pfizer declared a quarterly dividend of $0.43 per share (ex-dividend May 8, payable June 12), equal to an annualized $1.72 and roughly a 6.4% yield with a payout ratio of 126.47%.
• In the prior quarter Pfizer beat estimates with $0.66 EPS on $17.56 billion revenue; Wall Street consensus is a "Hold" with a $28.48 price target, and the stock has a market cap of about $152.5 billion and a one‑year range of $21.97–$28.75.

Pfizer (NYSE:PFE - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Pfizer to post earnings of $0.77 per share and revenue of $13.8941 billion for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the company posted $0.63 earnings per share. Pfizer's revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Stock Performance

Shares of PFE stock opened at $26.81 on Tuesday. Pfizer has a 1-year low of $21.97 and a 1-year high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $152.47 billion, a price-to-earnings ratio of 19.72 and a beta of 0.43. The stock's fifty day simple moving average is $27.22 and its 200-day simple moving average is $26.07.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer's payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. Royal Bank Of Canada reissued an "underperform" rating and set a $25.00 price objective on shares of Pfizer in a research report on Monday, April 20th. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. Daiwa Securities Group cut Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.48.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: High-yield appeal — Pfizer is listed among the "10 Best Fortune 500 Dividend Stocks" with an annual yield around 6.37%, keeping income-focused investors interested. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Positive Sentiment: Clinical supply agreement supports oncology pipeline commercialization — Relay Therapeutics reported clinical data and noted a supply agreement with Pfizer to supply atirmociclib, signaling an ongoing role for Pfizer in oncology supply chains and potential downstream revenue if programs advance. Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
• Positive Sentiment: Featured in high-yield dividend roundups — Popular retail-investor pieces (e.g., 247WallStreet) include Pfizer among high-yield candidates, which can attract income-seeking flows into the stock. Want $1,188 in Passive Income? Invest $5,000 Into These 3 High-Yielding Stocks
• Neutral Sentiment: Pfizer executive moves seen externally — Armata Pharmaceuticals appointed a former Pfizer commercial-quality executive to its board; this highlights Pfizer alumni influence but has limited direct impact on Pfizer’s fundamentals. Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors
• Neutral Sentiment: Market headlines outside Pfizer’s business — A major M&A move in the sector (Organon acquisition by Sun Pharma) is drawing merger-arb attention but doesn’t directly affect Pfizer’s operations. Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal
• Negative Sentiment: Competitive pressure from obesity leaders — Analyst and press comparisons with Novo Nordisk emphasize that Pfizer faces an uphill battle in obesity and related growth markets; investors may penalize Pfizer stock if they see slower growth or pipeline gaps versus market leaders. Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the stock. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the second quarter worth about $32,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth about $34,000. Birchwood Financial Partners Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth about $38,000. WFA of San Diego LLC acquired a new stake in shares of Pfizer in the second quarter worth about $40,000. Finally, Atlas Capital Advisors Inc. acquired a new position in Pfizer in the 4th quarter valued at $41,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.